ArticleFrontiers in immunology2020
Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Reframing thymic epithelial tumors through single-cell transcriptomics: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Surgical management of suspected paraneoplastic myasthenia gravis in rectal cancer during neoadjuvant immunotherapy: a case report.Frontiers in oncology · 2025Article
- Clinicopathological predictors of postoperative long-term myasthenic status in resected thymoma with myasthenia gravis.Surgery today · 2024Article
- Myasthenia gravis: the future is here.The Journal of clinical investigation · 2024Review
- Thymic gene expression analysis reveals a potential link between HIF-1A and Th17/Treg imbalance in thymoma associated myasthenia gravis.Journal of neuroinflammation · 2024Article
- The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis.European journal of neurology · 2024Article
- Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization.Biomedicines · 2023Article
- Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center.Journal of cardiothoracic surgery · 2023Article
- The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review.The British and Irish orthoptic journal · 2023Article
- Good's syndrome and COVID-19: case report and literature review.Mediastinum (Hong Kong, China) · 2023Article
- Thymus-derived hormonal and cellular control of cancer.Frontiers in endocrinology · 2023Review
- Novel pathophysiological insights in autoimmune myasthenia gravis.Current opinion in neurology · 2022Review
- Article
- The LINC00452/miR-204/CHST4 Axis Regulating Thymic Tregs Might Be Involved in the Progression of Thymoma-Associated Myasthenia Gravis.Frontiers in neurology · 2022Article
- MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells.Cytotechnology · 2021Article
- Article
- Immune-Related Molecular Profiling of Thymoma With Myasthenia Gravis.Frontiers in genetics · 2021Article
- Molecular pathology of thymomas: implications for diagnosis and therapy.Virchows Archiv : an international journal of pathology · 2021Review
- Inflammatory biomarker panels in peripheral blood: association with myasthenia gravis onset and severity.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A unique feature of thymomas is their unrivaled frequency of associated myasthenia gravis (MG). Previous studies reported that MG+ thymomas contain a larger number of mature "pre-emigrant" CD4+ T cells than MG- thymomas and that most thymomas do not contain AIRE expressing cells irrespective of MG status. These findings suggest that CD4+ T cells that mature inside the abnormal microenvironment of thymomas and egress to the blood are critical to the development of thymoma-associated MG (TAMG) irrespective of thymoma histotype. However, underlying mechanisms have remained enigmatic. To get hints to mechanisms underlying TAMG, we pursue three hypotheses: (i) Functional pathways with metabolic and immunological relevance might be differentially expressed in TAMG(+) compared to TAMG(-) thymomas; (ii) differentially enriched pathways might be more evident in immature lymphocyte-poor (i.e., tumor cell/stroma-rich) thymoma subgroups; and (iii) mechanisms leading to TAMG might be different among thymoma histological subtypes. To test these hypotheses, we compared the expression of functional pathways with potential immunological relevance (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.